Skip to content
Finance Investment, Oil Mining Resources

LTR Pharma Limited (ASX:LTP) – SPONTAN® Achieves Manufacturing Validation For Pivotal Clinical Study

LTR Pharma Limited (ASX:LTP) 2 mins read

• LTR Pharma has achieved manufacturing validation for its upcoming pivotal clinical study for its lead product, SPONTAN®.

• Essential criteria for a pivotal FDA clinical study have been met – including stability testing, quality control checks, product purity and packaging integrity.

• Patient recruitment for its bioequivalence study is due to commence this month.

LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”), a Company focused on improving men’s health through clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction (“ED”), SPONTAN®, is pleased to provide an update on the Company’s preparation for the product’s upcoming bioequivalence clinical study.

LTR Pharma, in conjunction with its Contract Manufacturing Organisation (CMO), has now successfully completed pivotal stability and quality control milestones for SPONTAN®. By testing the chemical stability of SPONTAN over three specified periods, whilst assessing packaging integrity and confirming purity of the active ingredients, LTR Pharma has now met key U.S. Food and Drug Administration (FDA) requirements to be considered a pivotal study.

Achieving this status signifies adherence to the highest product quality and regulatory standards and is an important step to support the start of clinical batch manufacturing and commencement of SPONTAN’s pivotal clinical study.

LTR Pharma Chairman, Lee Rodne, said: “This achievement has been underpinned by a comprehensive suite of quality control checks as mandated by the FDA. Each check was meticulously designed to evaluate the chemical stability of SPONTAN over specified time periods, assess the integrity of its packaging, and verify the purity of our nasal spray formulation. Completion of these critical steps signifies our Company’s commitment to adhering to the highest standards of product quality and regulatory compliance. We are optimistic about the potential impact of SPONTAN in the market and look forward to sharing our progress as we move closer to initiating the clinical trial.“

Patient recruitment for SPONTAN’s bioequivalence study is due to commence this month. The trial is a randomized, open-label, single-dose, two-treatment cross-over study that looks at how the body processes Vardenafil after giving it to 18 healthy adult men in the form of SONTAN Nasal Spray and Vardenafil Tablets.

About us:

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

Contact details:

Jane Morgan


More from this category

  • Finance Investment, Oil Mining Resources
  • 23/02/2024
  • 12:11
Critical Minerals Group (ASX:CMG)

Critical Minerals Group (ASX:CMG) Welcomes Groundbreaking Vanadium Battery Manufacturing Agreement in Townsville

Sydney, Australia 23 February 2024 - ASX listed vanadium developer, Critical Minerals Group (ASX:CMG), is thrilled to announce its enthusiastic support for the recent collaboration agreement that marks a significant milestone in the establishment of a vanadium flow battery manufacturing supply chain in Townsville, North Queensland. In a joint statement, Queensland Premier, The Honourable Steven Miles, and the Queensland Minister for Resources and Critical Minerals, The Honourable Scott Stewart, announced a non-binding collaboration agreement between Vecco Group, Sumitomo Electric, and Idemitsu. This group aims to manufacture, market, sell, and deliver batteries from North Queensland. Based on publicly announced projects, globally…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 23/02/2024
  • 11:08
Conrad Asia Energy Ltd (ASX:CRD)

Conrad Asia Energy Ltd (ASX:CRD) – Ministerial Approval of Mako Gas Price & Allocation

Conrad Asia Energy Ltd (ASX:CRD), a leading natural gas exploration and development company focused on Asia, is thrilled to announce a pivotal advancement in the Mako field project within the Duyung Production Sharing Contract (PSC). The Indonesian Minister of Energy and Natural Resources has officially approved the gas price and volume allocation for the Mako project, marking a significant milestone in the project's development and the country's energy sector. This approval, conveyed through an Allocation Letter from the Indonesian Minister of Mining and Natural Resources, sets the stage for Conrad to finalize fully termed Gas Sales Agreements (GSA). It signifies…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 23/02/2024
  • 10:47
American Rare Earths Limited (ASX: ARR)

American Rare Earths Limited (ASX: ARR) – A$13.5m Placement to advance Halleck Creek Project

American Rare Earths Limited (ASX: ARR | ADRs – OTCQX: AMRRY | Common Shares – OTCQB: ARRNF) (“ARR” or the “Company”), a leader in the exploration and development of critical minerals essential for the clean energy transition, is thrilled to announce the successful completion of a placement that raised A$13.5 million through the issuance of 45 million new fully paid ordinary shares at an issue price of A$0.30 per share (“Placement”). This significant capital injection was met with strong enthusiasm from both existing shareholders and new institutional investors, underscoring the market's confidence in ARR's strategic direction and its commitment to…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.